Evidence map›Paper›PMID 40758349›Full record

ArticleJAMA network open2025

Latent Profile Analysis of Childhood Maltreatment and Neural Markers in Depression.

Jessica Rowe, Nikita Nogovitsyn, Raegan Mazurka, Scott D Squires, Stefanie Hassel, Jordan Poppenk, Katharine Dunlop, Mojdeh Zamyadi, Roumen V Milev, Jane A Foster and 7 more

Abstract readMulticenter Study
In one paragraph

Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jessica RoweDepartment of Psychology, Queen's University, Kingston, Ontario, Canada.
Nikita NogovitsynMood Disorders Treatment and Research Centre, St Joseph's Healthcare, Hamilton, Ontario, Canada.
Raegan MazurkaDepartment of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada.
Scott D SquiresDepartment of Psychology, Queen's University, Kingston, Ontario, Canada.
Stefanie HasselDepartment of Psychiatry, University of Calgary, Calgary, Alberta, Canada.
Jordan PoppenkDepartment of Psychology, Queen's University, Kingston, Ontario, Canada.
Katharine DunlopCentre for Depression and Suicide Studies, St Michael's Hospital, Toronto, Ontario, Canada.
Mojdeh ZamyadiCentre for Addiction and Mental Health, Toronto, Ontario, Canada.
Roumen V MilevDepartment of Psychology, Queen's University, Kingston, Ontario, Canada.
Jane A FosterCenter for Depression Research and Clinical Care, Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas.
Stephen R ArnottRotman Research Institute, Baycrest, Toronto, Ontario, Canada.
Raymond W LamDepartment of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.
Rudolf UherDepartment of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada.
Susan RotzingerCentre for Depression and Suicide Studies, St Michael's Hospital, Toronto, Ontario, Canada.
Sidney H KennedyCentre for Depression and Suicide Studies, St Michael's Hospital, Toronto, Ontario, Canada.
Benicio N FreyMood Disorders Treatment and Research Centre, St Joseph's Healthcare, Hamilton, Ontario, Canada.
Kate L HarknessDepartment of Psychology, Queen's University, Kingston, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: The limited success of major depressive disorder (MDD) treatments is largely due to the disorder's etiological and pathophysiological heterogeneity. Addressing this heterogeneity is essential for developing accurate prognostic models and personalized treatment strategies. Objective: To characterize MDD heterogeneity using a mechanism-first latent profile analysis based on environmental, neurostructural, and neurofunctional indicators, and to validate profiles via associations with MDD course, severity, and antidepressant treatment remission. Design, Setting, and Participants: This cross-sectional study used data from 2 Canadian Biomarker Integration Network in Depression (CAN-BIND) studies: CAN-BIND-1 (2014-2017), a multicenter outpatient antidepressant trial, and CAN-BIND-4 (2015-2018), a single-site study. Data analyses were completed from February to September 2024. Participants meeting Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) diagnostic criteria for unipolar depression were included. Individuals with lifetime bipolar, psychotic, substance use disorder, acute suicidality, and neurological disorders were excluded. Exposure: In CAN-BIND-1, patients received 10 to 20 mg of escitalopram daily; nonresponders at 8 weeks received aripiprazole augmentation for 8 additional weeks. CAN-BIND-4 was observational. Main Outcomes and Measures: Primary outcomes were latent profiles derived from childhood maltreatment (CM; semistructured interview); hippocampal, amygdala, thalamus structural volume (SV); anterior cingulate thickness (image segmentation); and DMN functional connectivity (average time series of the blood oxygen level-dependent signal). Secondary outcomes included associations with MDD course, symptom severity (including anhedonia, measured using Montgomery-Åsberg Depression Rating Scale), and remission rates. Results: In a sample of 309 adults with clinical depression (mean [SD] age, 33.81 [13.17] years; 206 female [66.67%]), 4 profiles emerged: (1) low CM and high SV, (2) low CM and low SV, (3) high CM and high SV, and (4) high CM and low SV with default mode network hypoconnectivity. Profile 4 was associated with the worst course, with the highest morbidity (mean number of years of morbidity, 19.91 years; 95% CI, 12.45-20.69 years), anhedonia (mean, 10.72; 95% CI, 9.74-11.70), and lowest remission rate (mean, 21.5%; 95% CI, 17.6%-23.5%) at week 16. Profile 3 had the highest remission rates (mean, 90.9%; 95% CI, 63.4%-118.0%). Conclusions and Relevance: In this cross-sectional study of 309 adults with depression, 4 latent profiles were identified. Default mode network hypoconnectivity defined profile 4, supporting its role as a key neural indicator of antidepressant response. CM was associated with both the highest and lowest remission rates, indicating it does not uniformly project negative outcomes and suggesting that neurobiological resilience in the context of childhood trauma may have contributed to more favorable clinical outcomes; further research is needed to refine clinical applications.

Indexed as

Adult Survivors of Child AbuseMajor Depressive DisorderAdultAntidepressive AgentsAripiprazoleBiomarkersCanadaCross-Sectional StudiesEscitalopramFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedAntidepressive AgentsAripiprazoleBiomarkersEscitalopram

Identifiers

PMID40758349
PMCPMC12322798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.